Core Insights - Medicus Pharma Ltd. announced positive topline results from its Phase 2 clinical study (SKNJCT-003) for Doxorubicin Microneedle Array (D-MNA) aimed at treating basal cell carcinoma (BCC) of the skin, indicating potential for FDA engagement and partnership readiness [1][2] Clinical Study Design and Results - The SKNJCT-003 study was a randomized, double-blind, placebo-controlled trial involving 90 patients with nodular BCC, assessing two dose levels of D-MNA against a placebo [3] - The primary endpoint was defined as achieving both clinical and histological clearance at a specified post-treatment timepoint [3] - Topline results showed that at Day 29, the clinical clearance rates were 33% for placebo, 47% for 100µg D-MNA, and 40% for 200µg D-MNA; at Day 57, the rates improved to 38% for placebo, 42% for 100µg D-MNA, and 73% for 200µg D-MNA, with histological clearance rates of 20%, 24%, and 27% respectively at Day 29, and 38%, 33%, and 40% at Day 57 [4] Management Commentary - The CEO of Medicus expressed strong encouragement regarding the topline results, viewing them as decision-grade evidence of clinical activity, particularly at the 200µg dose level [5] - The increase in clearance rates at Day 57 supports the sustained biological activity of the treatment and enhances the company's position in potential partnership discussions [6] Regulatory and Strategic Focus - The final Clinical Study Report (CSR) is expected to be completed in Q2 2026, with no anticipated material changes to the reported efficacy findings [7] - The study was not powered for registrational endpoints, and no conclusions regarding regulatory approval can be drawn at this time [8] - Medicus aims to advance select programs through Phase 2 proof-of-concept and pursue strategic partnerships for late-stage development and commercialization [9]